Healthcare · Drug Manufacturers - Specialty & Generic
Price
$4.39
Market Cap
$436.0M
Employees
142
Beta
1.45
Avg Volume
1,604,138
CEO
Daniel Barber
Business Description
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-5.78
Stock Price: $4.39
EPS (Diluted): -0.76
EPS (Diluted): -0.76
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-23.41
Stock Price: $4.39
Total Equity: -$33.66M
Shares: 121,966,911
Total Equity: -$33.66M
Shares: 121,966,911
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-8.89
Market Cap: $435.96M
Total Debt: $127.11M
Cash: $121.17M
EBITDA: -$66.13M
Total Debt: $127.11M
Cash: $121.17M
EBITDA: -$66.13M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$798.2M
Market Cap: $435.96M
Total Debt: $127.11M
Cash: $121.17M
Total Debt: $127.11M
Cash: $121.17M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
17.69
Stock Price: $4.39
Revenue: $44.55M
Shares: 121,966,911
Revenue: $44.55M
Shares: 121,966,911
EV/Sales (Total value vs revenue — works when P/E can't)
API17.92
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
61.5%
Gross Profit: $27.39M
Revenue: $44.55M
Revenue: $44.55M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-156.4%
Operating Income: -$69.65M
Revenue: $44.55M
Revenue: $44.55M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-188.1%
Net Income: -$83.78M
Revenue: $44.55M
Revenue: $44.55M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
190.9%
Net Income: -$83.78M
Total Equity: -$33.66M
Total Equity: -$33.66M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-44.8%
Operating Income: -$69.65M
Tax Rate: 0.0%
Equity: -$33.66M
Total Debt: $127.11M
Cash: $121.17M
Tax Rate: 0.0%
Equity: -$33.66M
Total Debt: $127.11M
Cash: $121.17M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.14
Current Assets: $149.27M
Current Liabilities: $47.61M
Current Liabilities: $47.61M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-3.78
Short-Term Debt: $11.63M
Long-Term Debt: $115.48M
Total Debt: $127.11M
Total Equity: -$33.66M
Long-Term Debt: $115.48M
Total Debt: $127.11M
Total Equity: -$33.66M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.37
Revenue: $44.55M
Shares: 121,966,911
Shares: 121,966,911
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-0.28
Total Equity: -$33.66M
Shares: 121,966,911
Shares: 121,966,911
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.43
Operating CF: -$52.43M
CapEx: -$562,000
Shares: 121,966,911
CapEx: -$562,000
Shares: 121,966,911
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.39
Stock Price: $4.39
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$83.78M
Net Income: -$83.78M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AQST against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 6:32pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $50.8M | $47.7M | $50.6M | $57.6M | $44.5M |
| Cost of Revenue | $15.0M | $19.4M | $20.8M | $17.9M | $17.2M |
| Gross Profit | $35.8M | $28.3M | $29.8M | $39.7M | $27.4M |
| Operating Expenses | $70.5M | $70.4M | $44.9M | $70.5M | $97.0M |
| Operating Income | -$34.7M | -$42.1M | -$15.1M | -$30.8M | -$69.7M |
| Net Income | -$70.5M | -$54.4M | -$7.9M | -$44.1M | -$83.8M |
| EBITDA | -$45.1M | -$39.6M | $1.2M | -$26.6M | -$66.1M |
| EPS | $-1.85 | $-1.12 | $-0.13 | $-0.51 | $-0.76 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 6:32pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $28.0M | $27.3M | $23.9M | $71.5M | $121.2M |
| Total Current Assets | $47.3M | $39.9M | $41.0M | $88.2M | $149.3M |
| Total Assets | $62.0M | $57.1M | $57.4M | $101.4M | $160.4M |
| Current Liabilities | $22.0M | $39.5M | $18.3M | $18.9M | $47.6M |
| Long-Term Debt | $51.6M | $33.4M | $27.5M | $32.5M | $115.5M |
| Total Liabilities | $144.1M | $175.6M | $163.9M | $161.6M | $194.1M |
| Total Equity | -$82.1M | -$118.6M | -$106.5M | -$60.2M | -$33.7M |
| Retained Earnings | -$256.8M | -$311.2M | -$319.1M | -$363.2M | -$447.0M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 6:32pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$33.0M | -$9.8M | -$6.4M | -$35.8M | -$52.4M |
| Capital Expenditure | $-913,000 | -$2.5M | $-995,000 | $-159,000 | $-562,000 |
| Free Cash Flow | -$33.9M | -$12.3M | -$7.4M | -$35.9M | -$53.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$3.8M | $-751,000 | -$3.4M | $47.7M | $49.6M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 4:58am (4h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$71.7M $64.7M – $76.9M
|
$100.7M $86.6M – $122.7M
|
$168.6M $144.9M – $205.3M
|
$252.6M $217.1M – $307.7M
|
| EBITDA |
-$45.3M -$48.5M – -$40.9M
|
-$63.6M -$77.5M – -$54.6M
|
-$106.4M -$129.6M – -$91.5M
|
-$159.5M -$194.3M – -$137.1M
|
| Net Income |
-$48.0M -$68.9M – -$11.9M
|
-$46.4M -$56.1M – $1.0M
|
-$3.7M -$4.7M – -$3.0M
|
$25.0M $20.4M – $32.1M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 6:32pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -6.2% | +6.1% | +13.8% | -22.6% |
| Gross Profit Growth | -21.1% | +5.2% | +33.4% | -31.0% |
| Operating Income Growth | -21.3% | +64.1% | -103.8% | -126.4% |
| Net Income Growth | +22.9% | +85.5% | -460.8% | -89.8% |
| EBITDA Growth | +12.3% | +103.0% | -2,351.8% | -148.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 4:58am (4h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Krop Julie | M-Exempt | 25,000.00 | $0.71 | $17,830 |
| 2026-06-23 | Krop Julie | S-Sale | 25,000.00 | $5.02 | $125,393 |
| 2026-06-23 | Krop Julie | M-Exempt | 25,000.00 | $0.71 | $17,830 |
| 2026-06-15 | Barber Daniel | S-Sale | 25,000.00 | $4.16 | $104,010 |
| 2026-06-10 | MORRIS TIMOTHY E | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-10 | Krop Julie | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-10 | Jenkins Abigail L. | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-10 | Cochran John | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-10 | BROWN GREGORY B | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-10 | Taglietti Marco | A-Award | 50,500.00 | $3.99 | $201,495 |
| 2026-06-08 | Korczynski Sherry | F-InKind | 2,714.00 | $0.00 | $0 |
| 2026-05-18 | Zalewski Thomas A. | A-Award | 100,000.00 | $0.00 | $0 |
| 2026-05-18 | Zalewski Thomas A. | A-Award | 75,000.00 | $4.14 | $310,125 |
| 2026-05-15 | Barber Daniel | S-Sale | 8,257.00 | $4.29 | $35,413 |
| 2026-05-15 | Cioffi Melina | F-InKind | 1,667.00 | $4.17 | $6,951 |
| 2026-05-07 | BRAENDER LORI J | F-InKind | 135,690.00 | $4.23 | $573,969 |
| 2026-05-05 | Boyd Peter E. | F-InKind | 56,778.00 | $4.18 | $237,332 |
| 2026-05-05 | Barber Daniel | F-InKind | 335,922.00 | $4.18 | $1.4M |
| 2026-05-05 | TOTH A ERNEST JR | F-InKind | 92,652.00 | $4.18 | $387,285 |
| 2026-05-05 | Jung Cassie | F-InKind | 72,734.00 | $4.18 | $304,028 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for AQST — it's generated by the pipeline (
market-narrative step).
No community reviews yet for AQST.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30